New information on the role of beta-blockers in cardiac therapy

Cardiovascular Drugs and Therapy

Volumn 13, Issue 6, 1999, Pages 469-477

  Himmelmann, Anders ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angina pectoris; Beta blockers; Heart failure; Hypertension; Ischemic heart disease

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT;

ANGINA PECTORIS; DISEASE SEVERITY; DRUG EFFICACY; EXERCISE TOLERANCE; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; RISK; SYMPTOM;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CLINICAL TRIALS; HEART DISEASES; HYPERTENSION;

EID: 0033392115     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007893301243     Document Type: Review

References (72)

1. 1. The Committee on Evaluation and Management of Heart Failure. Guidelines for the evaluation and management of heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 1995;92:2764-2784.
2. 2. The Task Force on Heart Failure of the European Society of Cardiology. Guidelines for the diagnosis of heart failure. Eur Heart J 1995;16:741-751.
3. 3. The Task Force of the Working Group on Heart Failure of the European Society of Cardiology. The treatment of heart failure. Eur Heart J 1997; 18:736-753.
4. 4. Packer M, Cohn J, on behalf of the membership of the Advisory Council to Improve Outcomes Nationwide in Heart Failure. Consensus recommendations for the management of chronic heart failure. Am J Cardiol 1999;83(2A):1A-38A.
5. 5. Franciosa JA. Epidemiologic patterns, clinical evaluation, and long-term prognosis in chronic congestive heart failure. Am J Med 1986;80(2B):14-21.
6. 6. Cohn JN, Rector TS. Prognosis of congestive heart failure and predictors of mortality. Am J Cardiol 1988;62:25A-30A.
7. 7. Itoh A, Saito M, Haze K, Hiramori K, Kasagi F. Prognosis of patients with congestive heart failure: Its determinants in various heart diseases in Japan. Intern Med 1992;31:304-309.
8. 8. Ho KK, Anderson KM, Kannel WB, Grossman W, Levy D. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993;88:107-115.
9. 9. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J Am Coll Cardiol 1996;27: 1214-1218.
10. 10. Vasan RS, Levy D. The role of hypertension in the pathogenesis of heart failure. A clinical mechanistic overview. Arch Intern Med 1996;156:1789-1796.
11. 11. Deedwania PC. The progression from hypertension to heart failure. Am J Hypertens 1997;10(Part 2):280S-288S.
12. 12. Perera GA. Hypertensive vascular disease; description and natural history. J Chron Dis 1955;1:33-42.
13. 13. Levy D, Larsson MG, Vasan RS, Kannel WB, Ho KKL. The progression from hypertension to congestive heart failure. JAMA 1996;275:1557-1562.
14. 14. Cruickshank JM, Prichard BNC. Beta-blockers in Clinical Practice. Edinburgh: Churchill Livingstone, 1988.
15. 15. Ruffolo RR Jr, Gellai M, Hieble JP, Willette RN, Nichols AJ. The pharmacology of carvedilol. Eur J Clin Pharmacol 1990;38(Suppl 10);S82-S88.
16. 16. Lehtonen A, Transkanen A, Temmerman J. Effect of bucindolol on plasma HDL cholesterol subfractions and other plasma lipids in essential hypertensive patients, Int J Clin Pharmacol Ther Toxicol 1987;25:448-451.
17. 17. Collins R, Peto R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease. Part 2: Short-term reductions in blood pressure: Overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
18. 18. Lithell HOL. Effect of antihypertensive drugs on insulin, glucose and lipid metabolism. Diabetes Care 1991;14: 203-209.
19. 19. Jacob S, Rett K, Wicklmayr M, Agrawal B, Augustin HJ, Dietze GJ. Differential effect of chronic treatment with two beta-blocking agents on insulin sensitivity: The carvedilol-metoprolol study. J Hypertens 1996;14:489-494.
20. 20. Giugliano D, Acampora R, Marfella R, et al. Metabolic and cardiovascular effects of carvedilol and atenolol in non-insulin-dependent diabetes mellitus and hypertension. A randomized, controlled trial. Ann Intern Med 1997;126:955-959.
21. 21. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745.
22. 22. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly. JAMA 1998;279:1903-1907.
23. 23. Guidelines Subcommittee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999;17: 151-183.
24. 24. Zanchetti A, Chalmers JP, Arakawa K, et al. The 1993 guidelines for the management of mild hypertension memorandum from a WHO/ISH meeting. Blood Press 1993;2:86-100.
25. 25. Frimodt-Moeller J, Poulsen DL, Kornerup HJ, et al. Quality of life, side effects, and efficacy of lisinopril compared with metoprolol in patients with mild to moderate essential hypertension. J Hum Hypertens 1991;5:215-221.
26. 26. Ostergren J, Storstein L, Karlberg BE, Tibblin G. Quality of life in hypertensive patients treated with either carvedilol or enalapril. Blood Press 1996;5:41-49.
27. 27. The Task Force of the European Society of Cardiology. Management of stable angina pectoris. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997;18:394-413.
28. 28. The Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
29. 29. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 35:1001-1009.
30. 30. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged anti-platelet therapy in various categories of patients. BMJ 1994;308:81-106.
31. 31. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: An overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-371.
32. 32. Hjalmarson A, Olsson G. Myocardial infarction. Effects of beta-blockade. Circulation 1991;84(Suppl VI):VI-101-VI-107.
33. 33. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Cardiac Fail 1997;3:249-254.
34. 34. Xhignesse M, Laplante P, Grant AM, et al. Antiplatelet and lipid-lowering therapies for the secondary prevention of cardiovascular disease: Are we doing enough? Can J Cardiol 1999;15:185-189.
35. 35. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL. Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998;158:1238-1244.
36. 36. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1998;18:1569-1582.
37. 37. Gottlieb SS, McCarter RJ, Vogel RA. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. Lancet 1998;339(8):489-497.
38. 38. The Norwegian Multicenter Group. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304:801-807.
39. 39. Herlitz J, Hjalmarson A, Waagstein F. Effect of metoprolol among patients with suspected acute myocardial infarction and left ventricular dysfunction. Eur Heart J 1996; 17(Suppl):514.
40. 40. Hjalmarson A, Elmfeldt D, Herlitz J, et al. Effect on mortality of metoprolol in acute myocardial infarction. A double-blind randomised trial. Lancet 1981;2:823-827.
41. 41. Hjalmarson A, Herlitz J, Holmberg S, et al. The Göteborg metoprolol trial. Effects on mortality and morbidity in acute myocardial infarction. Circulation 1983;67(Suppl 1):I-26-I-32.
42. 42. Basu S, Senior R, Raval U, van der Does R, Bruchner T, Lahiri A. Beneficial effects of intravenous and oral carvedilol treatment in acute myocardial infarction. A placebo-controlled, randomized trial. Circulation 1997;96:183-191.
43. 43. Kjekshus J, Swedberg K. Treatment of heart failure. J Interm Med 1996;239;335-343.
44. 44. Smith TW, Kelly RA, Warner Stevenson L, Braunwald E. Management of heart failure. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular Medicine Philadelphia: W.B. Saunders, 1997;492-514.
45. 45. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987;316:1429-1435.
46. 46. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
47. 47. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993;342:821-828.
48. 48. Kober L, Torp-Pedersen C, Carlsen JE, et al., for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995;333:1670-1676.
49. 49. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992;327:669-677.
50. 50. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-691.
51. 51. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-533.
52. 52. Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigative Group. J Am Coll Cardiol 1993;22:955-962.
53. 53. Packer M, Gheorghiade M, Young JB, et al. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study. N Engl J Med 1993;329:1-7.
54. 54. Epstein SE, Braunwald E. The effect of beta adrenergic blockade on patterns of urinary sodium excretion: Studies in normal subjects and in patients with heart disease. Ann Intern Med 1997;65:20-27.
55. 55. Waagstein F, Hjalmarson A, Varnauskas E, Wallentin I. Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy. Br Heart J 1975;7:1022-1036.
56. 56. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Beneficial effects of long-term beta-blockade in congestive cardiomyopathy. Br Heart J 1980;44:117-133.
57. 57. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Adverse effects of beta-blockade withdrawal in patients with congestive cardiomyopathy. Br Heart J 1980;44:134-142.
58. 58. Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A. Long-term beta-blockade in dilated cardiomyopathy. Effects of short-and long-term metoprolol treatment followed by withdrawal and readministration of metoprolol. Circulation 1989;80:551-563.
59. 59. Swedberg K, Hjalmarson A, Waagstein F, Wallentin I. Prolongation of survival in congestive cardiomyopathy by beta-receptor blockade. Lancet 1979;1:1374-1376.
60. 60. Waagstein F, Bristow MR, Swedberg K, et al. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993;342:1441-1446.
61. 61. CIBIS Investigators and Committees. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). Circulation 1994;90:1765-1773.
62. 62. Australia-New Zealand Heart Failure Research Collaborative Group. Randomised, placebo-controlled trial of carvedilol in patients with congestive heart failure due to ischemic heart disease. Lancet 1997;349:375-380.
63. 63. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular remodeling with carvedilol in patients with congestive heart failure due to ischemic heart disease. J Am Coll Cardiol 1997;29:1060-1066.
64. 64. Packer M, Bristow MR, Cohn JN, et al., for the US Carvedilol Heart Failure Study. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-1355.
65. 65. Colucci WS, Packer M, Bristow MR, et al., for the US Carvedilol Heart Failure Study. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. Circulation 1996;94:2800-2806.
66. 66. Bristow MR, Gilbert EM, Abraham WT, et al., for the MOCHA Investigators. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation 1996;94: 2807-2816.
67. 67. Packer M, Colucci WS, Sackner-Bernstein JD, et al., for the PRECISE Study Group. Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure The PRECISE Trial. Circulation 1996;94:2793-2799.
68. 68. Cohn JN, Fowler MB, Bristow MR, et al., for the US Carvedilol Heart Failure Study Group. Safety and efficacy of carvedilol in severe heart failure J Cardiac Failure 1997;3:173-179.
69. 69. Lechat P, Packer M, Chalon S, et al. Clinical effects of beta-adrenergic blockade in chronic heart failure. Circulation 1998;98:1184-1191.
70. 70. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial. Lancet 1999;353:9-13.
71. 71. MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure. Lancet 1999;353: 2001-2007
72. 72. Doughty RN, Rodgers A, Sharpe N, et al. Effects of beta blocker therapy on mortality in patients with heart failure: a systematic overview of randomised controlled trials. Eur Heart J 1997;8:560-565.